Aarhus Universitets segl

Mikkel Breinholt Kjær

Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


  • WJH-14-827

    Forlagets udgivne version, 2,59 MB, PDF-dokument


Natriuretic peptides are involved in the cascade of pathophysiological events
occurring in liver cirrhosis, counterbalancing vasoconstriction and anti-natriuretic factors. The effects of natriuretic peptides as treatment of cirrhotic ascites have been investigated only in small studies, and definitive results are lacking.

To examine the effects and safety of natriuretic peptides in cirrhosis patients with ascites.

We searched MEDLINE, Web of Science, Scopus, Cochrane Library and Embase
for all available studies applying intravenous administration of any natriuretic
peptide to patients suffering from cirrhotic ascites. Inclusion was not limited by
treatment duration or dose, or by follow-up duration. Both randomised controlled trials and non-randomised studies were eligible for inclusion. The primary outcome was change in renal sodium excretion. Secondary outcomes included safety measures and changes in renal water excretion, plasma aldosterone concentration, and plasma renin activity.

Twenty-two studies were included. Atrial natriuretic peptide (ANP) was the only
intensively studied treatment. Sodium excretion increased in response to continuous ANP infusion and was more pronounced when infusion rates of > 30 ng/kg/min were administered compared with ≤ 30 ng/kg/min (P < 0.01). Moreover, natriuresis was significantly higher in study subgroups with mild/moderate ascites compared with moderate/severe and refractory ascites (P < 0.01). ANP infusions increased renal water excretion, although without
reaching a statistically significant dose-response gradient. Plasma aldosterone concentration and plasma renin activity were significantly lower at baseline in study subgroups achieving a negative sodium balance in response to an ANP administration compared with treatment non-responders (P < 0.01). Blood pressure decreases occurred less frequently when ANP doses ≤ 30 ng/kg/min
were applied. The quality of evidence for a natriuretic response to ANP was low, mainly due to small sample sizes and considerable between-study heterogeneity. Data were sparse for the other natriuretic peptides; B-type natriuretic peptide and urodilatin.

Intravenous ANP infusions increase sodium excretion in patients with cirrhotic ascites. Continuous infusion rates > 30 ng/kg/min are the most effective. However, safety increases with infusion rates ≤ 30 ng/kg/min.
TidsskriftWorld Journal of Hepatology
Sider (fra-til)827-845
Antal sider19
StatusUdgivet - apr. 2022


  • atrial natriuretic peptide, B-type natriuretic peptide, Urodilatin, Cirrhosis, Ascites, Refractory ascites

Se relationer på Aarhus Universitet Citationsformater

ID: 264657149